Compare Becton Dickinson and Co (BDX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Atlassian Corporation PLC — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Atlassian Corporation PLC trades at $90.15 (market cap $22.62B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays a 2.79% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| BDX | TEAM | |
|---|---|---|
Market Cap | $41.51B | $22.62B |
Sector | Health | Technology |
52-Week High | $185.39 | $203.00 |
52-Week Low | $135.49 | $57.15 |
Enterprise Value | $57.97B | $22.73B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Atlassian (TEAM) trades at $96.11, up 8.16% today, with strong technical momentum and bullish analyst sentiment. The stock shows accelerating revenue growth (32% YoY in Q3 FY26 per Zacks Investment Research, 2026-06-24) and improving margins, though it remains unprofitable. Recent earnings beats and cloud business expansion support positive outlook, while high valuation multiples and competitive pressures present risks.
Outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent net losses and elevated valuation. Wall Street consensus price target of $115.69 suggests 20% upside, though execution on profitability is critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
